Underweight: Trim 25-35% into confirmed resistance; full Hold on broken momentum is an alpha leak per 9/28 binding lesson
UNDERWEIGHT captures the asymmetry: trim into confirmed resistance to harvest both defensive yield retention and momentum-prohibition discipline, hedge the binary, and define reload triggers in advance so the catalyst pass doesn't require real-time courage. The aggressive analyst is correct on trajectory-over-multiple but overcommits on magnitude (30-50%) and has stop placement problems (1× ATR). The conservative analyst is correct on floor thesis but underweights the 9/28 binding lesson that full-Hold in broken momentum is itself an alpha leak. The 9/28 binding reflection overrides the structural valuation case when timing is wrong and the most recent empirical outcome (prior full-Hold calibration) produced -1.4% alpha vs SPY. The current setup is functionally identical to the 9/22 and 9/28 configurations that produced alpha leakage on full sizing. Do NOT rotate into PFE or other correlated pharma as hedge per COP 9/28 cross-ticker lesson. Income mandates: collect 3.94% dividend on retained 65-75%; total-return mandates: preserve trimmed capital in short-duration Treasuries at 5%+ rather than redeploy into validated alpha-leaking configuration.
| Position | Action |
|---|---|
| Close >$64.00 with negative MACD histogram (50 SMA resistance confirmed) | Trim 25-35% of existing BMY exposure into $63.50-$64.00 zone |
| Failed test at 50 SMA / close back below $63 with declining momentum | Confirm 50 SMA holding as resistance before executing trim |
| Move above $63.80-$64.00 | Sell with tight execution, accepting fill won't be perfect |
| Retained 65-75% position approach stop level | Protective stop at $57.50 (just below 200 SMA at $58.55) |
BMY's 9.6x forward P/E fully prices in known patent cliff risks while ignoring pipeline catalysts (Cobenfy $4-6B peak, Krazati $3-4B peak) that will replace Eliquis erosion, combined with a compelling deleveraging trajectory and defensive characteristics at an historically depressed multiple.
| Indicator | Value | Signal |
|---|---|---|
| close_50_sma | 64.47 | bearish |
| close_200_sma | 58.55 | bullish |
| rsi | 45.24 | neutral |
| boll_ub | 67.91 | neutral |
| boll_lb | 60.13 | neutral |
| macd | -0.63 | bearish |
| macds | -0.49 | bearish |
| atr | 1.40 | neutral |
Support: 60.13 · 60 · 61.15 | Resistance: 64.47 · 67.91 · 68.09
BMY is in a defensive consolidation phase following a ~10% pullback from its September 3 high of $68.09 to a Sep 23 low of $61.15, with the Sep 29 close at $62.86. The strategic trend remains bullish (price 7.4% above the 200 SMA at 58.55), but tactical momentum is bearish (price below 50 SMA at 64.47, MACD/signal both negative). The report recommends HOLD with a stop below $60.00 and a bullish trigger on a daily close above 64.47 with contracting MACD histogram.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed 50 SMA reclaim at $64.47 with volume >15M AND MACD histogram positive AND RSI>50
Then: Reload trimmed exposure
The patent cliff is priced in and the pipeline will replace lost revenue
↩ rebuts: “Bear's patent cliff narrative ignores portfolio replacement; Cobenfy is first novel mechanism for schizophrenia in decades”
EV: +15% on multiple expansion alone (9.58x to 11x); Target 1 at $67.91 (~8% upside), Target 2 at $68.64 (52-week high retest) · concedes: Patent cliff is real and Eliquis LOE in 2026 will impact near-term earnings; EPS growth will appear stagnant in near-term projections due to Revlimid erosion and Eliquis LOE; D/E ratio of 2.55x is elevated versus 1.31x pre-acquisition; MACD cross and price below 50 SMA are valid technical warning signals; Rising 30-year Treasury yields create headwind for dividend stocks
BMY's "cheap" valuation is a value trap reflecting structural impairment from accelerating patent cliffs, over-promised pipeline candidates, unsustainable leverage, and bearish technical momentum—not a buying opportunity.
EV: -$15 to -20% (to $54-55 target) · concedes: BMY does have a low absolute multiple and a covered dividend—those are facts; D/E direction of travel is technically accurate; A 10% pullback from $68 to $61 did occur; Recession probability of 8% is relatively low; Dividend has been maintained to date
→ vs conservative: The 6.3% FCF yield cited as a floor was violated when BMY traded to $42 in 2024; cheap valuation is not safety when the earnings denominator is structurally compromised — cheap for a reason IS the bear case
→ vs conservative: 200 SMA at $58.55 is not a level that prevents aggressive action; static support fails in confirmed breakdowns and does not hold "because we need it to"
→ vs neutral: Macro backdrop (higher-for-longer rates, 4.5%+ Treasury benchmark, 96% probability of zero Fed cuts) eliminates BMY's yield advantage and removes the defensive bid floor that justified the neutral stance
→ vs neutral: "No actionable sentiment signal" is incorrect — the silence IS the signal: absence of marginal buyers ahead of binary Q3 catalyst means no one lined up to defend $60 if print disappoints; neutral is maximum uncertainty, not low risk
Market Cap
$128.4 B
Share Price (implied)
~$62.86
52-Week Range
$42.52 – $68.64
50-Day MA
$64.42
200-Day MA
$59.20
P/E (TTM)
13.85x
Forward P/E
9.58x
PEG Ratio
17.79
P/B
5.75x
Dividend Yield
3.94%
Beta
0.227
EPS (TTM)
$4.54
Forward EPS
$6.56
Total Revenue (2025)
$48,195 M
Total Revenue (2024)
$48,300 M
Total Revenue (2023)
$45,006 M
Operating Revenue (2025)
$47,203 M
Gross Profit (2025)
$34,259 M
Operating Income (2025)
$13,724 M
Operating Income (2024)
$5,887 M
EBITDA (GAAP) (2025)
$15,230 M
EBITDA (GAAP) (2024)
$3,168 M
Normalized EBITDA (2025)
$19,945 M
Normalized EBITDA (2024)
$17,100 M
Net Income (2025)
$7,054 M
Net Income (2024)
($8,948) M
Diluted EPS (2025)
$3.46
Diluted EPS (2024)
($4.41)
R&D Spend (2025)
$9.95 B
R&D Spend (2024)
$11.16 B
SG&A (2025)
$7.27 B
Operating Margin (TTM)
34.4%
Gross Margin
~71%
Cash & ST Investments (2025)
$10,673 M
Total Debt (2025)
$47,139 M
Total Debt (2024)
$51,200 M
Net Debt (2025)
$34,902 M
Net Debt (2024)
$39,303 M
Stockholders' Equity (2025)
$18,473 M
Stockholders' Equity (2024)
$16,335 M
Stockholders' Equity (2023)
$29,430 M
Total Assets (2025)
$90,038 M
Goodwill + Intangibles (2025)
$41,107 M
Goodwill + Intangibles (2022)
$57,504 M
Tangible Book Value (2025)
($22,634) M
Current Ratio (2025)
1.53
Debt/Equity (2025)
2.55x
Debt/Equity (2024)
3.13x
Debt/Equity (2022)
1.31x
Net Debt/EBITDA (normalized)
~1.75x
Operating Cash Flow (2025)
$14,156 M
Capital Expenditures (2025)
($1,311) M
Free Cash Flow (2025)
$12,845 M
Free Cash Flow (2024)
$13,942 M
Free Cash Flow (TTM)
$8.1 B
FCF Yield
~6.3%
Dividends Paid (2025)
$5,045 M
Dividends Paid (2022)
$4,634 M
Dividend Coverage by FCF
~2.5x
Net Business Purchases (2024)
($20,722) M
Net Stock Repurchases (2024)
$0
Net Debt Issuance (2025)
($5,175) M
ROE
46.6%
ROA
10.7%
Net Margin (TTM)
18.9%
Total Unusual Items (2024)
$13.9 B
IPR&D / Acquisition / Restructuring Charge (2024)
$14.34 B
Depreciation & Amortization (2024)
$9.6 B
Karuna Therapeutics Acquisition
~$14B (2024)
Mirati Therapeutics Acquisition
~$4.8B (2024)
Strengths
Concerns
Bristol-Myers Squibb presents as a high-quality, defensive pharmaceutical stock trading at a compelling forward P/E of 9.58x with strong free cash flow generation of ~$12.8B annually and a well-covered 3.94% dividend yielding ~2.5x coverage by FCF. The principal risks are elevated leverage (2.55x D/E) following ~$14B Karuna and ~$4.8B Mirati acquisitions in 2024, the upcoming Eliquis patent cliff in 2026, and ongoing Revlimid generic erosion, while Cobenfy (schizophrenia) and Krazati (NSCLC) offer potential long-term growth catalysts alongside the deep oncology/hematology portfolio.
Macro: "Higher for longer" regime reasserting with 30-year Treasury at highest level since 2002, mortgage rates at 7.58% approaching 3-year highs, and 96% probability priced for zero Fed rate cuts in 2026. Moody's Zandi warns higher rates are damaging the economy. US recession probability remains low at 8%. Stronger dollar (from widening yield differentials) is a mild headwind to BMY's international revenue mix.